Global B Cell Lymphoma Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 6,360.75 Billion |
 Market Size (Forecast Year) |
USD 13,145.36 Billion |
 CAGR |
% |
| Major Markets Players |
|
全球 B 细胞淋巴瘤治疗市场，按类型（弥漫性大 B 细胞淋巴瘤 (DLBCL)、淋巴浆细胞性淋巴瘤、毛细胞白血病、原发性中枢神经系统 (CNS) 淋巴瘤、原发性眼内淋巴瘤、其他）、分期（I 期、II 期、III 期、IV 期、其他）、治疗（放疗、化疗、免疫疗法、干细胞移植、其他）、最终用户（医院、专科诊所、家庭医疗保健、其他）、分销渠道（直接招标、医院药房、零售药房、网上药房、其他）划分 - 行业趋势和预测到 2030 年。
B 细胞淋巴瘤治疗市场分析和规模
淋巴瘤是一种起源于淋巴细胞的癌症。霍奇金淋巴瘤和非霍奇金淋巴瘤是淋巴瘤的两种主要类型。B 细胞淋巴瘤是非霍奇金淋巴瘤。在非霍奇金淋巴瘤患者中，约 85% 患有 B 细胞淋巴瘤。
据美国癌症协会称，大约四分之三的人在初次治疗后不会出现任何疾病迹象，而且许多人都已治愈。毛细胞白血病 (HCL) 很罕见，美国每年约有 700 人被诊断出患有此病。
Data Bridge Market Research 分析，B 细胞淋巴瘤治疗市场规模在 2022 年为 6,360.75 美元，到 2030 年将飙升至 13,145.36 百万美元，预计在预测期内的复合年增长率为 8.4%。由于病例数量不断增加且患病率不断上升，“弥漫性大 B 细胞淋巴瘤 (DLBCL)”在 B 细胞淋巴瘤治疗市场类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
B 细胞淋巴瘤治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按类型（弥漫性大 B 细胞淋巴瘤 (DLBCL)、淋巴浆细胞性淋巴瘤、毛细胞白血病、原发性中枢神经系统 (CNS) 淋巴瘤、原发性眼内淋巴瘤、其他）、分期（I 期、II 期、III 期、IV 期、其他）、治疗（放疗、化疗、免疫疗法、干细胞移植、其他）、最终用户（医院、专科诊所、家庭医疗保健、其他）、分销渠道（直接招标、医院药房、零售药房、网上药房、其他） |
|
覆盖国家 |
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America |
|
Market Players Covered |
Pfizer Inc. (U.S.), Celgene Corporation (U.S.), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), Genentech Inc. (U.S.), AstraZeneca (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd (Japan), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S), Johnson & Johnson Services (U.S.), Abbott. (U.S.), Takeda Pharmaceutical Company Ltd. (Japan), and Seattle Genetics, Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
B-cell lymphoma treatment encompasses a range of therapeutic approaches to combating cancerous B-cells in the lymphatic system. Chemotherapy remains a cornerstone in managing B-cell lymphomas, often combined with targeted therapies. Immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, have revolutionized treatment outcomes for specific B-cell lymphoma subtypes. Research efforts focus on personalized medicine approaches to tailor treatment based on individual patient characteristics and the identification of novel therapeutic targets. The ultimate goal of B-cell lymphoma treatment is to achieve remission, improve patient outcomes, and enhance the quality of life for individuals affected by this disease.
B-cell Lymphoma Treatment Market Dynamics
Drivers
- Increasing Incidence of B-cell lymphomas
The incidence of B-cell lymphomas, including subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), is rising globally. The growing patient population drives the demand for effective treatment options and fuels the expansion of the market.
- Advancements in Treatment options
The continuous advancements in treatment options have significantly improved outcomes for B-cell lymphoma patients. Targeted therapies, immunotherapies, and CAR-T cell therapies have emerged as powerful tools in the fight against B-cell lymphomas, driving market growth and offering new treatment options.
Opportunities
- Advancements in Targeted Therapies:
Targeted therapies, such as monoclonal antibodies and small molecule inhibitors, have shown promising results in treating B-cell lymphomas. There is an opportunity to refine and expand targeted therapies to improve treatment outcomes, minimize side effects, and overcome resistance mechanisms.
- Rising Personalized Medicine
The advancement of precision medicine approaches and the identification of predictive biomarkers can help tailor treatment strategies for individual patients. This includes using genomic profiling and molecular diagnostics to identify specific genetic alterations and biomarkers that can guide treatment decisions and enhance therapeutic outcomes.
Restraints/Challenges
Various obstacles may restrain the expansion of the B-cell lymphoma treatment market. These challenges include costly treatments, adverse effects associated with long-term therapies, development of drug resistance. These factors can impede market growth and pose barriers for market players in the forecast period of 2023-2030.
This B-cell lymphoma treatment Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the B-cell lymphoma treatment Market, contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
-
In March 2023, Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of or are refractory to, first-line chemoimmunotherapy. This approval covers all European Union (EU) member states. This has helped the company to expand its product portfolio
-
In March 2023, AstraZeneca announced that Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This has helped the company to expand its product portfolio.
Global B-cell Lymphoma Treatment Market Scope
The B-cell lymphoma treatment market is segmented on the basis of type, stages, treatment, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Lymphoplasmacytic Lymphoma
- Hairy Cell Leukemia
- Primary Central Nervous System (CNS) Lymphoma
- Primary Intraocular Lymphoma
- Others
Stages
- Stage I
- Stage II
- Stage III
- Stage IV
- Others
Treatment
- Radiation
- Chemotherapy
- Immune Therapy
- Stem Cell Transplant
- Others
End Users
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Direct Tender
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
B-cell Lymphoma Treatment Market Regional Analysis/Insights
The B-cell lymphoma treatment Market is analyzed and market size insights and trends are provided by country, type, stages, treatment end user and distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America is dominating the market due to the presence of an-advanced healthcare system supporting strong research and development activities for B-cell lymphoma treatment and also due to the increased consumption of oncology drugs for cancer treatment.
Asia-Pacific is expected to grow the market in the forecast period of 2023-2030 because of rising healthcare infrastructure and government and pharmaceutical initiatives for better treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The B-cell lymphoma treatment Market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for B-cell lymphoma treatment Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the B-cell lymphoma treatment Market. The data is available for historic period 2010-2020.
Competitive Landscape and B-cell lymphoma treatment Market Share Analysis
B 细胞淋巴瘤治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对 B 细胞淋巴瘤治疗市场的关注有关。
B 细胞淋巴瘤治疗市场的一些主要参与者包括：
- 辉瑞公司（美国）
- Celgene 公司 (美国)
- 礼来公司 (美国)
- 诺华公司（瑞士）
- 基因泰克公司（美国）
- 阿斯利康（英国）
- F. Hoffmann-La Roche Ltd（瑞士）
- 卫材株式会社（日本）
- 安进公司 (美国)
- 默克公司（美国）
- 百时美施贵宝公司 (美国)
- 强生服务公司（美国）
- 雅培（美国）
- 武田药品工业株式会社（日本）
- 西雅图遗传学公司（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
